KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zimmer Biomet Holdings (ZBH) Research & Development (2016 - 2025)

Zimmer Biomet Holdings (ZBH) has 17 years of Research & Development data on record, last reported at $118.7 million in Q4 2025.

  • For Q4 2025, Research & Development rose 9.4% year-over-year to $118.7 million; the TTM value through Dec 2025 reached $458.5 million, up 4.82%, while the annual FY2025 figure was $458.5 million, 4.82% up from the prior year.
  • Research & Development reached $118.7 million in Q4 2025 per ZBH's latest filing, up from $115.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $165.0 million in Q2 2021 and bottomed at $81.0 million in Q1 2021.
  • Average Research & Development over 5 years is $110.6 million, with a median of $109.9 million recorded in 2023.
  • Peak YoY movement for Research & Development: soared 88.98% in 2021, then crashed 39.76% in 2022.
  • A 5-year view of Research & Development shows it stood at $96.0 million in 2021, then rose by 12.5% to $108.0 million in 2022, then grew by 4.91% to $113.3 million in 2023, then fell by 4.24% to $108.5 million in 2024, then increased by 9.4% to $118.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $118.7 million in Q4 2025, $115.9 million in Q3 2025, and $113.3 million in Q2 2025.